Obermatt
See Similar Stocks →

AC Immune

NMQ:ACIU · CH0329023102
BiotechnologySmall

360

68
Medium confidence — indicative
Profit price—
Cash yield1
Price/Sales52
Price/Book7
Return on Capital23
Return on Equity16
Profit margins27

Cash truth not applicable for financial companies.

Sales growth93
Profit growth34
Reinvestment65
Price momentum61
Debt load56
Debt serviceability4
Liquidity14
Analyst ratings100
Opinion Changes50
Price Target Upside100
Market mood45
Value Creation0/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

AC Immune doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Based on 3/5 components.

Profile

CountrySwitzerland
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Founded2003
Employees147
Websiteacimmune.com
ISINCH0329023102
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Health DiagnosticsImmunologyNeurologyChronic DiseasesNeuroscienceOncologyVaccinesCentral Nervous SystemGeneticsBiotechnologyPharmaceuticalTherapeutics

Description

AC Immune SA (AC Immune), a clinical stage biopharmaceutical company, focuses on pioneering precision medicine for neurodegenerative diseases. The company's highly differentiated approach integrates novel therapeutics and diagnostics to overcome the…

Analysis

Middle-of-the-road

AC Immune SA is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is solid and the balance sheet is adequate. The company scores 0/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
18
2026

All-time high

18

Jun 2026

All-time low

13

Mar 2026

Average rank

16

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
52
—
—
—
Price/Earnings
59
—
—
—
Price/Book
7
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
21
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare AC Immune with its peers
Prothena Corporation
NSQ:PRTA
39
CountryIreland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Immatics
NAQ:IMTX
31
CountryGermany
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Galapagos
AEX:GLPG
76
CountryBelgium
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
ABIVAX
PAR:ABVX
26
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Immunocore
NSQ:IMCR
40
CountryUK
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
OKYO Pharma
NAQ:OKYO
40
CountryUK
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →